Skip to main content
. 2021 Jul 23;9:698639. doi: 10.3389/fcell.2021.698639

FIGURE 5.

FIGURE 5

Inhibition of breast cancer cells but not non-tumorigenic cells by NK3.3-derived EV treatment in vitro. (A–D) Dose response analyses were performed using concentrations of EVs ranging from 1 to 100 μg/ml or PBS (0). Cells were monitored daily using a crystal violet viability assay. MDA-MB-231 cells were treated with either (A) HEK293 EVs or (B) NK3.3 EVs, and MCF7 cells treated with either (C) HEK293 EVs or (D) NK3.3 EVs. Mean absorbance ± SE; n = 3. (E) HEK293 embryonic kidney cells were treated with the same increasing NK3.3 EV concentrations and stained with crystal violet. (F) IL-2 stimulated peripheral blood lymphocytes from a healthy donor were treated with 25 or 75 μg/ml of either HEK293 EVs or NK3.3 EVs; metabolic activity was monitored using WST-1. Mean absorbance ± SE; n = 3. p-Values determined by comparison of NK3.3 EV-treated cells at each treatment concentration to HEK293 EV-treated cells at the corresponding EV concentration. *p ≤ 0.05, **p ≤ 0.005, ***p ≤ 0.0005.